AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 32236553 — intervention group
Group type: EXPERIMENTAL
Intervention: Band and plate fixation (plates)
Number of subjects: 50
Study 32236553 — intervention group
Group type: COMPARATOR
Intervention: Figure-of-8 wire cerclage (wires)
Number of subjects: 50
Study 33998255 — intervention group
Group type: EXPERIMENTAL
Intervention: 0/1-hour unmasked hs-cTnT protocol (reported to <5 ng/L)
Number of subjects: 3270
Study 33998255 — intervention group
Group type: COMPARATOR
Intervention: 0/3-hour masked hs-cTnT protocol (reported to ≤29 ng/L)
Number of subjects: 3270
Study 33998255 — intervention group
Group type: EXPERIMENTAL
Intervention: 0/1-hour unmasked hs-cTnT protocol (reported to <5 ng/L) among participants with initial troponin T concentrations ≤29 ng/L
Number of subjects: 3270
Study 33998255 — intervention group
Group type: COMPARATOR
Intervention: 0/3-hour masked hs-cTnT protocol (reported to ≤29 ng/L) among participants with initial troponin T concentrations ≤29 ng/L
Number of subjects: 3270
Study 32445576 — intervention group
Group type: EXPERIMENTAL
Intervention: Drug-Coated Balloon (DCB)
Number of subjects: 115
Study 32445576 — intervention group
Group type: COMPARATOR
Intervention: Conventional Stenting (non-DCB)
Number of subjects: 115
Study 35265146 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupoint catgut embedding (ACE)
Number of subjects: 216
Study 35265146 — intervention group
Group type: COMPARATOR
Intervention: Sham acupoint catgut embedding (sham ACE)
Number of subjects: 216
Study 35265146 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupoint catgut embedding (ACE) in males
Number of subjects: 216
Study 35265146 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupoint catgut embedding (ACE) in females
Number of subjects: 216
Study 32151791 — intervention group
Group type: EXPERIMENTAL
Intervention: Stroop condition
Number of subjects: 0
Study 32151791 — intervention group
Group type: EXPERIMENTAL
Intervention: Reverse Stroop condition
Number of subjects: 0
Study 32151791 — intervention group
Group type: COMPARATOR
Intervention: Overall responses in reverse Stroop condition
Number of subjects: 0
Study 32151791 — intervention group
Group type: EXPERIMENTAL
Intervention: Experiments 3 and 4
Number of subjects: 0
Study 32151791 — intervention group
Group type: EXPERIMENTAL
Intervention: Experiment 5
Number of subjects: 0
Study 33565017 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyaluronic acid (HA)
Number of subjects: 32
Study 33565017 — intervention group
Group type: COMPARATOR
Intervention: Enamel matrix derivative (EMD)
Number of subjects: 32
Study 33196656 — intervention group
Group type: COMPARATOR
Intervention: Genetically predicted BMI of 30 kg/m2
Number of subjects: 55908
Study 36196872 — intervention group
Group type: EXPERIMENTAL
Intervention: Resilience and Coping for the Healthcare Community (RCHC)
Number of subjects: 762
Study 36196872 — intervention group
Group type: EXPERIMENTAL
Intervention: Resilience and Coping for the Healthcare Community expanded version (RCHC+)
Number of subjects: 762
Study 32910353 — intervention group
Group type: EXPERIMENTAL
Intervention: Free at-home HIV testing
Number of subjects: 151
Study 32910353 — intervention group
Group type: COMPARATOR
Intervention: Home Access HIV-1 test kit
Number of subjects: 151
Study 33578226 — intervention group
Group type: EXPERIMENTAL
Intervention: Enoxaparin 20 mg twice a day starting 24 h after onset of ICH
Number of subjects: 139
Study 33578226 — intervention group
Group type: COMPARATOR
Intervention: Placebo starting 72 h after onset of ICH
Number of subjects: 139
Study 33578226 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups received intermittent pneumatic compression stockings
Number of subjects: 139
Study 33578226 — intervention group
Group type: EXPERIMENTAL
Intervention: Enoxaparin group
Number of subjects: 139
Study 33578226 — intervention group
Group type: COMPARATOR
Intervention: Placebo group
Number of subjects: 139
Study 33578226 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 139
Study 32352351 — intervention group
Group type: EXPERIMENTAL
Intervention: Ambar Universal APS (AMB-APS)
Number of subjects: 0
Study 32352351 — intervention group
Group type: EXPERIMENTAL
Intervention: Ambar Universal (AMB)
Number of subjects: 0
Study 32352351 — intervention group
Group type: EXPERIMENTAL
Intervention: Scotchbond Universal (SBU)
Number of subjects: 0
Study 36191863 — intervention group
Group type: EXPERIMENTAL
Intervention: Large gaze duration (80% of conversation time)
Number of subjects: 62
Study 36191863 — intervention group
Group type: EXPERIMENTAL
Intervention: Small gaze duration (20% of conversation time)
Number of subjects: 62
Study 36191863 — intervention group
Group type: COMPARATOR
Intervention: Patients with SAD
Number of subjects: 62
Study 36191863 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls (HCs)
Number of subjects: 62
Study 34495988 — intervention group
Group type: EXPERIMENTAL
Intervention: ChAd63 CAT vaccine (three-antigen: CSP, AMA1, ME-TRAP)
Number of subjects: 40
Study 34495988 — intervention group
Group type: EXPERIMENTAL
Intervention: ChAd63 CA vaccine (two-antigen: CSP, AMA1)
Number of subjects: 40
Study 34495988 — intervention group
Group type: COMPARATOR
Intervention: Infectivity controls
Number of subjects: 40
Study 33012603 — intervention group
Group type: EXPERIMENTAL
Intervention: Trivalent inactivated influenza vaccine (IIV3)
Number of subjects: 0
Study 33012603 — intervention group
Group type: EXPERIMENTAL
Intervention: Inactivated polio vaccine (IPV)
Number of subjects: 0
Study 35045323 — intervention group
Group type: EXPERIMENTAL
Intervention: Planful, Healthful and Frequent Family Evening Meals (C3)
Number of subjects: 114
Study 35045323 — intervention group
Group type: EXPERIMENTAL
Intervention: Family Evening Meals with Fast Food (C2)
Number of subjects: 114
Study 35045323 — intervention group
Group type: EXPERIMENTAL
Intervention: Unplanned Infrequent Family Evening Meals with Mixed Healthfulness (C1)
Number of subjects: 114
Study 34057392 — intervention group
Group type: EXPERIMENTAL
Intervention: Brolucizumab
Number of subjects: 0
Study 32559602 — intervention group
Group type: EXPERIMENTAL
Intervention: Vilaprisan
Number of subjects: 155
Study 32559602 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 155
Study 32559602 — intervention group
Group type: EXPERIMENTAL
Intervention: Ulipristal acetate
Number of subjects: 155
Study 35798178 — intervention group
Group type: EXPERIMENTAL
Intervention: Mirtazapine
Number of subjects: 101
Study 35798178 — intervention group
Group type: EXPERIMENTAL
Intervention: SSRI
Number of subjects: 101
Study 33955262 — intervention group
Group type: EXPERIMENTAL
Intervention: Endurance exercise (cycling)
Number of subjects: 34
Study 33955262 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance exercise (leg-extension)
Number of subjects: 34
Study 33955262 — intervention group
Group type: EXPERIMENTAL
Intervention: Four weeks of exercise training (END and RT)
Number of subjects: 34
Study 32273162 — intervention group
Group type: EXPERIMENTAL
Intervention: PGT‐A group
Number of subjects: 0
Study 32273162 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study 35168962 — intervention group
Group type: EXPERIMENTAL
Intervention: Desmopressin
Number of subjects: 123
Study 35168962 — intervention group
Group type: EXPERIMENTAL
Intervention: VWF-containing concentrate
Number of subjects: 123
Study 35168962 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of desmopressin and VWF-containing concentrate
Number of subjects: 123
Study 35168962 — intervention group
Group type: EXPERIMENTAL
Intervention: VWF-containing concentrate (prophylaxis)
Number of subjects: 123
Study 35168962 — intervention group
Group type: EXPERIMENTAL
Intervention: Desmopressin (bleeding episodes)
Number of subjects: 123
Study 35168962 — intervention group
Group type: EXPERIMENTAL
Intervention: VWF-containing concentrate (bleeding episodes)
Number of subjects: 123
Study 35168962 — intervention group
Group type: EXPERIMENTAL
Intervention: Desmopressin (medical procedures)
Number of subjects: 123
Study 35168962 — intervention group
Group type: EXPERIMENTAL
Intervention: VWF-containing concentrate (medical procedures)
Number of subjects: 123
Study 35168962 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of desmopressin and VWF-containing concentrate (medical procedures)
Number of subjects: 123
Study 35168962 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall treatment
Number of subjects: 123
Study 33761651 — intervention group
Group type: EXPERIMENTAL
Intervention: Real ear acupuncture once a week for 8 weeks
Number of subjects: 0
Study 33761651 — intervention group
Group type: COMPARATOR
Intervention: Sham ear acupuncture once a week for 8 weeks
Number of subjects: 0
Study 35248123 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical monitoring alone
Number of subjects: 0
Study 35248123 — intervention group
Group type: COMPARATOR
Intervention: Laboratory and clinical monitoring
Number of subjects: 0
Study 33629185 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher waist circumference (WC)
Number of subjects: 127997
Study 33629185 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher waist-to-hip ratio (WHR)
Number of subjects: 127997
Study 32224326 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulsed radiofrequency (PRF) treatment
Number of subjects: 10
Study 32224326 — intervention group
Group type: COMPARATOR
Intervention: Sham treatment
Number of subjects: 10
Study 35100752 — intervention group
Group type: EXPERIMENTAL
Intervention: Triple LET (3 applications of Lidocaine 4%, epinephrine 0.1%, and tetracaine 0.5% every 10 minutes)
Number of subjects: 48
Study 35100752 — intervention group
Group type: COMPARATOR
Intervention: Single LET (1 application of Lidocaine 4%, epinephrine 0.1%, and tetracaine 0.5% for 30 minutes)
Number of subjects: 48
Study 35100752 — intervention group
Group type: COMPARATOR
Intervention: Single LET
Number of subjects: 48
Study 35100752 — intervention group
Group type: EXPERIMENTAL
Intervention: Triple LET
Number of subjects: 48
Study 33967755 — intervention group
Group type: COMPARATOR
Intervention: Standard of Care (SoC)
Number of subjects: 590
Study 33967755 — intervention group
Group type: COMPARATOR
Intervention: Lopinavir/ritonavir (LPV/r)
Number of subjects: 590
Study 33967755 — intervention group
Group type: COMPARATOR
Intervention: Hydroxychloroquine (HCQ)
Number of subjects: 590
Study 33967755 — intervention group
Group type: COMPARATOR
Intervention: HCQ + LPV/r
Number of subjects: 590
Study 35588887 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxycycline 100 mg oral twice a day for three days before CPB
Number of subjects: 36
Study 35588887 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study 34937388 — intervention group
Group type: EXPERIMENTAL
Intervention: Evacetrapib (130 mg); placebo-adjusted percent increase in apoA1 in HDL that contains apoC3: 99%.
Number of subjects: 206
Study 34937388 — intervention group
Group type: EXPERIMENTAL
Intervention: Torcetrapib (60 mg); placebo-adjusted percent increase in apoA1 in HDL that contains apoC3: 50%.
Number of subjects: 206
Study 34937388 — intervention group
Group type: EXPERIMENTAL
Intervention: Both CETP inhibitors; increase in apoA1 in HDL that contains apoC1: 71% (evacetrapib) and 40% (torcetrapib).
Number of subjects: 206
Study 34937388 — intervention group
Group type: EXPERIMENTAL
Intervention: Both CETP inhibitors; no response in HDL that contains apoL1.
Number of subjects: 206
Study 33476880 — intervention group
Group type: EXPERIMENTAL
Intervention: Alemtuzumab
Number of subjects: 811
Study 33476880 — intervention group
Group type: COMPARATOR
Intervention: SC IFNB‐1a
Number of subjects: 811
Study 32050940 — intervention group
Group type: EXPERIMENTAL
Intervention: GPAQ with show cards
Number of subjects: 54
Study 32050940 — intervention group
Group type: COMPARATOR
Intervention: GPAQ without show cards
Number of subjects: 54
Study 35620899 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraoperative Portable CT Scan (PCT)
Number of subjects: 60
Study 32514702 — intervention group
Group type: EXPERIMENTAL
Intervention: Medial midpatellar (MMP) injection of hyaluronic acid (HA)
Number of subjects: 100
Study 32514702 — intervention group
Group type: COMPARATOR
Intervention: Anteromedial (AM) injection of hyaluronic acid (HA)
Number of subjects: 100
Study 32208774 — intervention group
Group type: EXPERIMENTAL
Intervention: E2 + norethisterone
Number of subjects: 14
Study 32208774 — intervention group
Group type: EXPERIMENTAL
Intervention: E2 + progesterone
Number of subjects: 14
Study 32208774 — intervention group
Group type: EXPERIMENTAL
Intervention: E2 + dydrogesterone
Number of subjects: 14
Study 32208774 — intervention group
Group type: COMPARATOR
Intervention: E2 + placebo
Number of subjects: 14
Study 35037049 — intervention group
Group type: EXPERIMENTAL
Intervention: PCV-10
Number of subjects: 347
Study 35037049 — intervention group
Group type: COMPARATOR
Intervention: PPV-23
Number of subjects: 347
Study 35037049 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 347
Study 35478159 — intervention group
Group type: EXPERIMENTAL
Intervention: Ghost Ileostomy (GI)
Number of subjects: 54
Study 35478159 — intervention group
Group type: COMPARATOR
Intervention: Loop Ileostomy (LI)
Number of subjects: 54
Study 35478159 — intervention group
Group type: COMPARATOR
Intervention: No Outlet (NO)
Number of subjects: 54
Study 36201552 — intervention group
Group type: EXPERIMENTAL
Intervention: Robotics-assisted insertion
Number of subjects: 12
Study 36201552 — intervention group
Group type: COMPARATOR
Intervention: Manual insertion
Number of subjects: 12
Study 33421446 — intervention group
Group type: EXPERIMENTAL
Intervention: OligoG CF-5/20 therapy
Number of subjects: 58
Study 33421446 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 58
Study 32162241 — intervention group
Group type: EXPERIMENTAL
Intervention: WP-MND (1 or 2 servings daily, 21 g protein, 3 g leucine, 10 µg vitD, 500 mg calcium per serving)
Number of subjects: 380
Study 32162241 — intervention group
Group type: EXPERIMENTAL
Intervention: WP-MND (1 or 2 servings daily) during OLE
Number of subjects: 380
Study 32162241 — intervention group
Group type: COMPARATOR
Intervention: Control group (placebo)
Number of subjects: 380
Study 35536485 — intervention group
Group type: EXPERIMENTAL
Intervention: EEBS‐26 cm
Number of subjects: 117
Study 35536485 — intervention group
Group type: EXPERIMENTAL
Intervention: EEBS‐30 cm
Number of subjects: 117
Study 35536485 — intervention group
Group type: COMPARATOR
Intervention: CPBS
Number of subjects: 117
Study 33599537 — intervention group
Group type: EXPERIMENTAL
Intervention: Axillary vein puncture guided by ultrasound (US‐Ax)
Number of subjects: 88
Study 33599537 — intervention group
Group type: COMPARATOR
Intervention: Cephalic vein dissection
Number of subjects: 88
Study 33882918 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-port laparoscopy
Number of subjects: 95
Study 33746207 — intervention group
Group type: EXPERIMENTAL
Intervention: Dissolvable collagen punctal plugs (CPP)
Number of subjects: 64
Study 33746207 — intervention group
Group type: COMPARATOR
Intervention: No intervention (Control group)
Number of subjects: 64
Study 32833890 — intervention group
Group type: EXPERIMENTAL
Intervention: Maintenance dose of 1.2 g·d‐1 Beta-Alanine
Number of subjects: 44
Study 32833890 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 44
Study 32833890 — intervention group
Group type: COMPARATOR
Intervention: Interruption of supplementation
Number of subjects: 44
Study 32973143 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness instruction (MT) group
Number of subjects: 0
Study 32973143 — intervention group
Group type: COMPARATOR
Intervention: Instructed thinking (IT) group
Number of subjects: 0
Study 34699772 — intervention group
Group type: EXPERIMENTAL
Intervention: Diesel exhaust (DE300)
Number of subjects: 29
Study 34699772 — intervention group
Group type: COMPARATOR
Intervention: Filtered air (FA)
Number of subjects: 29
Study 34656202 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Couple Therapy (CBCT)
Number of subjects: 108
Study 34656202 — intervention group
Group type: COMPARATOR
Intervention: Topical Lidocaine
Number of subjects: 108
Study 33604698 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased plasma levels of ABO protein
Number of subjects: 0
Study 33604698 — intervention group
Group type: EXPERIMENTAL
Intervention: OAS1
Number of subjects: 0
Study 36510286 — intervention group
Group type: EXPERIMENTAL
Intervention: mHealth app
Number of subjects: 0
Study 33754207 — intervention group
Group type: EXPERIMENTAL
Intervention: Chest X-ray (CXR) performed
Number of subjects: 597
Study 33754207 — intervention group
Group type: COMPARATOR
Intervention: No CXR performed (control group)
Number of subjects: 597
Study 34494361 — intervention group
Group type: EXPERIMENTAL
Intervention: New method targeting the marginal mean function for a composite endpoint including death as a component and as a competing risk
Number of subjects: 0
Study 34494361 — intervention group
Group type: COMPARATOR
Intervention: Standard time-to-first event analyses
Number of subjects: 0
Study 34562766 — intervention group
Group type: EXPERIMENTAL
Intervention: Prospective paper fall calendars
Number of subjects: 25
Study 34562766 — intervention group
Group type: EXPERIMENTAL
Intervention: Real-time body-worn self-reporting
Number of subjects: 25
Study 34562766 — intervention group
Group type: EXPERIMENTAL
Intervention: Automated body-worn detector
Number of subjects: 25
Study 32572082 — intervention group
Group type: EXPERIMENTAL
Intervention: Genotype Baiana at location 1
Number of subjects: 3
Study 32572082 — intervention group
Group type: EXPERIMENTAL
Intervention: Genotypes under hot semi-arid climate and tropical wet and dry climate
Number of subjects: 3
Study 32572082 — intervention group
Group type: EXPERIMENTAL
Intervention: Genotypes in restricted climatic conditions
Number of subjects: 3
Study 35986348 — intervention group
Group type: EXPERIMENTAL
Intervention: Prisma intervention (psychoeducational group intervention) consisting of four weekly group sessions.
Number of subjects: 186
Study 33973539 — intervention group
Group type: EXPERIMENTAL
Intervention: Systemic estrogen therapy
Number of subjects: 8
Study 33973539 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 32105162 — intervention group
Group type: EXPERIMENTAL
Intervention: EndoVac
Number of subjects: 60
Study 32105162 — intervention group
Group type: EXPERIMENTAL
Intervention: RinsEndo
Number of subjects: 60
Study 32105162 — intervention group
Group type: EXPERIMENTAL
Intervention: Passive ultrasonic activation
Number of subjects: 60
Study 32105162 — intervention group
Group type: EXPERIMENTAL
Intervention: EndoActivator
Number of subjects: 60
Study 32105162 — intervention group
Group type: COMPARATOR
Intervention: Manual needle irrigation
Number of subjects: 60
Study 35165682 — intervention group
Group type: EXPERIMENTAL
Intervention: Pitavastatin calcium
Number of subjects: 7736
Study 35165682 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7736
Study 34288556 — intervention group
Group type: EXPERIMENTAL
Intervention: Dehydrated (USG > 1.020, MDehy, FDehy, LDehy)
Number of subjects: 19
Study 34288556 — intervention group
Group type: COMPARATOR
Intervention: Euhydrated (USG ≤ 1.020, MEuhy, FEuhy, LEuhy)
Number of subjects: 19
Study 32729068 — intervention group
Group type: EXPERIMENTAL
Intervention: Agomelatine
Number of subjects: 1484
Study 35775843 — intervention group
Group type: EXPERIMENTAL
Intervention: Routine splenic flexure mobilization (SFM+), n=156
Number of subjects: 223
Study 35775843 — intervention group
Group type: COMPARATOR
Intervention: Control group (SFM(-)), n=67
Number of subjects: 223
Study 33092331 — intervention group
Group type: EXPERIMENTAL
Intervention: Dynamic stretching
Number of subjects: 8
Study 33092331 — intervention group
Group type: EXPERIMENTAL
Intervention: Static stretching
Number of subjects: 8
Study 33092331 — intervention group
Group type: COMPARATOR
Intervention: Control (no stretching)
Number of subjects: 8
Study 35920051 — intervention group
Group type: EXPERIMENTAL
Intervention: Panavia F2.0 (PF2.0)
Number of subjects: 24
Study 35920051 — intervention group
Group type: COMPARATOR
Intervention: Panavia V5 (PV5)
Number of subjects: 24
Study 32111316 — intervention group
Group type: COMPARATOR
Intervention: 1% dietary linoleic acid (LA1%)
Number of subjects: 24
Study 32111316 — intervention group
Group type: COMPARATOR
Intervention: 2% dietary linoleic acid (LA2%)
Number of subjects: 24
Study 32111316 — intervention group
Group type: COMPARATOR
Intervention: 4% dietary linoleic acid (LA4%)
Number of subjects: 24
Study 32111316 — intervention group
Group type: EXPERIMENTAL
Intervention: Control group
Number of subjects: 24
Study 34281376 — intervention group
Group type: EXPERIMENTAL
Intervention: Endovascular treatment
Number of subjects: 206
Study 34281376 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline glucose <150 mg/dL
Number of subjects: 206
Study 34281376 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower baseline NIH Stroke Scale
Number of subjects: 206
Study 34281376 — intervention group
Group type: EXPERIMENTAL
Intervention: Older age
Number of subjects: 206
Study 34281376 — intervention group
Group type: EXPERIMENTAL
Intervention: Internal carotid artery lesion location
Number of subjects: 206
Study 34281376 — intervention group
Group type: EXPERIMENTAL
Intervention: 24-hour ASPECTS
Number of subjects: 206
Study 34281376 — intervention group
Group type: EXPERIMENTAL
Intervention: Elevated baseline serum glucose ?150 mg/dL
Number of subjects: 206
Study 34281376 — intervention group
Group type: EXPERIMENTAL
Intervention: Internal carotid artery occlusion
Number of subjects: 206
Study 34281376 — intervention group
Group type: COMPARATOR
Intervention: Treatment arm
Number of subjects: 206
Study 35679195 — intervention group
Group type: EXPERIMENTAL
Intervention: Business case
Number of subjects: 410
Study 35679195 — intervention group
Group type: COMPARATOR
Intervention: Fairness case
Number of subjects: 410
Study 35679195 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 410
Study 34446499 — intervention group
Group type: EXPERIMENTAL
Intervention: Lumboperitoneal shunt (LPS)
Number of subjects: 0
Study 34446499 — intervention group
Group type: COMPARATOR
Intervention: Ventriculoperitoneal shunt (VPS)
Number of subjects: 0
Study 32349223 — intervention group
Group type: EXPERIMENTAL
Intervention: Recreational volleyball training (RV group)
Number of subjects: 24
Study 32349223 — intervention group
Group type: COMPARATOR
Intervention: Control group (CON)
Number of subjects: 24
Study 34979996 — intervention group
Group type: EXPERIMENTAL
Intervention: Sufficient leisure-time physical activity (LTPA) defined as ≥600 Met minutes per week
Number of subjects: 238
Study 34979996 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivation to be physically active during pregnancy
Number of subjects: 238
Study 34979996 — intervention group
Group type: EXPERIMENTAL
Intervention: Age and family income as factors affecting LTPA
Number of subjects: 238